Mutations in the BRAF gene, particularly the V600E mutation, are among the most clinically relevant biomarkers in precision oncology. These mutations drive uncontrolled tumour growth and are strongly associated with multiple cancers, including melanoma, colorectal cancer, thyroid cancer, and lung cancer. Detecting BRAF mutations is crucial not only for confirming diagnosis, but also for guiding targeted therapy decisions. By enabling oncologists to identify patients eligible for BRAF inhibitor therapies, BRAF testing directly contributes to better outcomes and improved survival rates.
To address this important clinical need, Genes2Me introduces the BRAF-Q Real-Time PCR Kit — a next-generation molecular diagnostic solution designed for the qualitative detection of BRAF somatic mutations in DNA extracted from fresh, frozen, or FFPE (formalin-fixed paraffin-embedded) clinical samples. Powered by advanced Real-Time PCR technology, this kit offers high sensitivity, specificity, and reliability, giving clinicians and laboratories confidence in results that directly influence oncology diagnosis, prognosis, and treatment planning.
The BRAF-Q Kit utilises ARMS (Amplification Refractory Mutation System) chemistry in combination with TaqMan probe technology to enable highly sensitive and specific detection of BRAF somatic mutations, including V600E, even at low mutant allele frequencies within a wild-type background. An integrated BRAF Internal Control (IC) validates DNA quality, workflow integrity, and reagent performance in every run, minimising the risk of false-negative results. The optimised, ready-to-use reagent format simplifies reaction setup, reduces contamination risk, and delivers reliable performance across diverse clinical sample types.
BRAF mutation testing is a cornerstone of precision oncology, enabling patient stratification, targeted therapy selection, and avoidance of ineffective treatments. The ability to detect clinically actionable mutations at very low frequencies makes this kit a powerful tool in personalised medicine. For patients with BRAF V600E mutations, early detection enables access to BRAF inhibitor therapies, significantly improving prognosis and quality of life. With greater than 99% sensitivity and specificity, the BRAF-Q Kit provides laboratories with dependable molecular diagnostic performance across melanoma, colorectal cancer, thyroid cancer, lung cancer, and other BRAF-driven malignancies.
Ready-to-use reagents simplify testing, reduce contamination risk, and deliver accurate mutation status within hours to support timely clinical decision-making.
Detects low levels of mutant DNA within a wild-type background using ARMS and TaqMan probe chemistry, with greater than 99% analytical sensitivity and specificity.
Greater than 99% sensitivity and specificity ensures confidence across diverse clinical oncology applications.
Integrated BRAF Internal Control (IC) validates DNA quality, workflow integrity, and reagent performance in every run, minimising false-negative results.
Validated on leading Real-Time PCR platforms including Thermo Fisher QuantStudio™ 5, Bio-Rad CFX96, Roche LightCycler® 480, and Genes2Me RapiCycler 96.
Optimised for fresh tissue, frozen samples, and FFPE specimens, making it adaptable for routine clinical use.
With the BRAF-Q Real-Time PCR Kit, laboratories can achieve highly sensitive, reproducible, and clinically meaningful detection of BRAF somatic mutations. By supporting early diagnosis, targeted therapy selection, and improved clinical evaluation across multiple cancers, the kit helps clinicians make informed decisions for patient care and disease management. Empower your laboratory with the BRAF-Q Real-Time PCR Kit — because timely molecular insights can make a lasting difference in patient outcomes.
When the Ct value of the sample to be tested is outside the reference range and there is a typical S-shaped amplification curve, the test result is positive; When the Ct value of the sample to be tested is within the reference range, or the Ct value is outside the reference range but there is no typical S-shaped amplification curve, the test result is negative.
| Commercial Name | Old Cat No. | New Cat No. | Pack Size |
|---|---|---|---|
| BRAF-Q Real-Time PCR Kit | G2M708521 | G610049-1 | 25 Tests |
Since its inception in 2016, Genes2me has been constantly striving towards setting a benchmark in the diagnostics space by introducing premium quality (Made in India) diagnostic kits which are CE-IVD, ISO-13485:2016, and ISO 9001:2015 certified, assuring our clients of unparalleled quality and compliance with international standards.
© 2025 Genes2me. All rights reserved.
